Identification
- Summary
Isoxsuprine is a beta-adrenergic agonist used in the symptomatic treatment of cerebrovascular insufficiency, peripheral vascular disease of arteriosclerosis obliterans, thromboangiitis obliterans (Buerger's disease) and Raynaud's disease.
- Generic Name
- Isoxsuprine
- DrugBank Accession Number
- DB08941
- Background
A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.
- Type
- Small Molecule
- Groups
- Approved, Withdrawn
- Structure
Structure for Isoxsuprine (DB08941)
- Weight
- Average: 301.386
Monoisotopic: 301.167793605 - Chemical Formula
- C18H23NO3
- Synonyms
- Isoxsuprine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbaloparatide The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Abaloparatide. Acebutolol The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Acebutolol. Aceclofenac The risk or severity of hypertension can be increased when Aceclofenac is combined with Isoxsuprine. Acemetacin The risk or severity of hypertension can be increased when Isoxsuprine is combined with Acemetacin. Acetylsalicylic acid The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Isoxsuprine. Aclidinium The risk or severity of Tachycardia can be increased when Aclidinium is combined with Isoxsuprine. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Isoxsuprine. Alclofenac The risk or severity of hypertension can be increased when Isoxsuprine is combined with Alclofenac. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isoxsuprine. Alfentanil The risk or severity of hypertension can be increased when Alfentanil is combined with Isoxsuprine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Isoxsuprine hydrochloride V74TEQ36CO 579-56-6 QVPSGVSNYPRFAS-BQZDIUEZSA-N - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Isoxsuprine Hydrochloride Tablet 20 mg/1 Oral Eci Pharmaceuticals Llc 2011-08-23 2025-03-31 US 
Isoxsuprine Hydrochloride Tablet 20 mg/1 Oral Vedco Dba Valdar 2011-08-23 Not applicable US Isoxsuprine Hydrochloride Tablet 20 mg/1 Oral Physicians Total Care, Inc. 1996-06-12 2011-06-30 US Isoxsuprine Hydrochloride Tablet 20 mg/1 Oral BI-COASTAL PHARMA INTERNATIONAL LIMITED LIABILITY COMPANY 2011-06-02 Not applicable US Isoxsuprine Hydrochloride Tablet 10 mg/1 Oral Eci Pharmaceuticals Llc 2011-06-02 2024-09-30 US Isoxsuprine Hydrochloride Tablet 20 mg/1 Oral Bi-Coastal Pharmaceutical Corporation 2011-06-02 Not applicable US Isoxsuprine Hydrochloride Tablet 10 mg/1 Oral Syntho Pharmaceuticals Inc. 2020-06-11 Not applicable US Isoxsuprine Hydrochloride Tablet 10 mg/1 Oral BI-COASTAL PHARMA INTERNATIONAL LIMITED LIABILITY COMPANY 2011-06-02 Not applicable US Isoxsuprine Hydrochloride Tablet 10 mg/1 Oral Bi-Coastal Pharmaceutical Corporation 2011-06-02 Not applicable US Isoxsuprine Hydrochloride Tablet 10 mg/1 Oral Syntho Pharmaceuticals Inc. 2020-02-06 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Isoxsuprine Hydrochloride Isoxsuprine hydrochloride (10 mg/1) Tablet Oral BI-COASTAL PHARMA INTERNATIONAL LIMITED LIABILITY COMPANY 2011-06-02 Not applicable US Isoxsuprine Hydrochloride Isoxsuprine hydrochloride (20 mg/1) Tablet Oral Vedco Dba Valdar 2011-08-23 Not applicable US Isoxsuprine Hydrochloride Isoxsuprine hydrochloride (10 mg/1) Tablet Oral Eci Pharmaceuticals Llc 2011-06-02 2024-09-30 US Isoxsuprine Hydrochloride Isoxsuprine hydrochloride (20 mg/1) Tablet Oral Physicians Total Care, Inc. 1996-06-12 2011-06-30 US Isoxsuprine Hydrochloride Isoxsuprine hydrochloride (10 mg/1) Tablet Oral Syntho Pharmaceuticals Inc. 2020-06-11 Not applicable US Isoxsuprine Hydrochloride Isoxsuprine hydrochloride (20 mg/1) Tablet Oral Vista Pharmaceuticals, Inc. 1997-09-19 Not applicable US Isoxsuprine Hydrochloride Isoxsuprine hydrochloride (20 mg/1) Tablet Oral Bi-Coastal Pharmaceutical Corporation 2011-06-02 Not applicable US Isoxsuprine Hydrochloride Isoxsuprine hydrochloride (10 mg/1) Tablet Oral Syntho Pharmaceuticals Inc. 2020-02-06 Not applicable US Isoxsuprine Hydrochloride Isoxsuprine hydrochloride (20 mg/1) Tablet Oral Eci Pharmaceuticals Llc 2011-08-23 2025-03-31 US Isoxsuprine Hydrochloride Isoxsuprine hydrochloride (10 mg/1) Tablet Oral Bi-Coastal Pharmaceutical Corporation 2011-06-02 Not applicable US
Categories
- ATC Codes
- C04AA01 — Isoxsuprine
- Drug Categories
- 2-Amino-1-Phenylethanol Derivatives
- Adrenergic Agents
- Adrenergic Agonists
- Adrenergic beta-Agonists
- Agents producing tachycardia
- Agents that produce hypertension
- Alcohols
- Amines
- Amino Alcohols
- Autonomic Agents
- Cardiovascular Agents
- Ethylamines
- Hypotensive Agents
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- Peripheral Vasodilators
- Phenethylamines
- Propanolamines
- Propanols
- Reproductive Control Agents
- Sympathomimetics
- Tocolytic Agents
- Vasodilating Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Phenylpropanes
- Direct Parent
- Phenylpropanes
- Alternative Parents
- Phenoxy compounds / Phenol ethers / Aralkylamines / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Hydrocarbon derivatives / Aromatic alcohols
- Substituents
- 1,2-aminoalcohol / 1-hydroxy-2-unsubstituted benzenoid / Alcohol / Alkyl aryl ether / Amine / Aralkylamine / Aromatic alcohol / Aromatic homomonocyclic compound / Ether / Hydrocarbon derivative
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- R15UI3245N
- CAS number
- 395-28-8
- InChI Key
- BMUKKTUHUDJSNZ-HBUWYVDXSA-N
- InChI
- InChI=1S/C18H23NO3/c1-13(12-22-17-6-4-3-5-7-17)19-14(2)18(21)15-8-10-16(20)11-9-15/h3-11,13-14,18-21H,12H2,1-2H3/t13-,14-,18-/m1/s1
- IUPAC Name
- 4-[(1S,2R)-1-hydroxy-2-{[(2R)-1-phenoxypropan-2-yl]amino}propyl]phenol
- SMILES
- C[C@H](COC1=CC=CC=C1)N[C@H](C)[C@@H](O)C1=CC=C(O)C=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 11779629
- PubChem Substance
- 310264908
- ChemSpider
- 9954311
- 6066
- ZINC
- ZINC000009302317
- Wikipedia
- Isoxsuprine
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1, 2 Completed Treatment Multiple Sclerosis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Tablet Oral 10 mg/1 Tablet Oral 20 mg/1 Tablet Oral Tablet Oral 10 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0507 mg/mL ALOGPS logP 2.06 ALOGPS logP 2.56 Chemaxon logS -3.8 ALOGPS pKa (Strongest Acidic) 9.65 Chemaxon pKa (Strongest Basic) 9 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 61.72 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 86.64 m3·mol-1 Chemaxon Polarizability 34.12 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at May 26, 2014 21:29 / Updated at February 21, 2021 18:52